59
Days Left
Lead Plaintiff Deadline
Nov 16, 2026
Please Upload related files below
Fill in below.
Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.
According to the filed complaint, defendants made false and/or misleading statements and/or failed to disclose that: Doximity claimed that the Company’s Newsfeed was its “biggest revenue driver.” Specifically, defendants claimed that the Company’s growth was “led by our newsfeed, which is both our most used and most monetized product” and told investors that the newsfeed was consistently “reaching new highs,” with “an all-time record of quarterly active prescribers and double-digit growth in the number of articles read or tapped.” In addition, Doximity touted its “deep engagement,” assuring investors that Doximity does not “bombard physicians with ads and messages in hopes of getting lucky” and assured investors that “Doximity does not have an e-newsletter product, In truth, Doximity overstated the impact that its newsfeed had on its revenue growth, and the Company was losing market share to its competitors with more favorable pricing and engagement models. Additionally, notwithstanding its frequent statements to the contrary, Doximity relied heavily on both banner ads and email newsletters as advertising methods.
Investors who purchased or otherwise acquired Doximity, Inc. securities within the class period described above and suffered losses may be eligible.
If you suffered a loss in Doximity, Inc. during the relevant time frame or pursuant to the relevant offering(s), you have until November 16, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
● The Allegation: The complaint alleges Doximity made materially false and misleading statements, overstating the impact its "Newsfeed" advertising product had on revenue growth while allegedly losing market share to competitors with more favorable pricing and engagement models, and relying on banner ads and email newsletters despite publicly denying it used such methods.
● The Stock Drop: Following the May 13, 2026 disclosure, DOCS fell $5.38 per share, or 23%, from $23.39 on May 13 to $18.01 on May 14 after the company missed its already-reduced revenue guidance and projected significantly slower growth for fiscal 2027; earlier, on November 6, 2025, DOCS fell $8.29 per share (13%) after the company signaled caution on ad spending and an implied slowdown in second-half sales growth; and on February 5, 2026, DOCS fell $5.59 per share (17%) after the company lowered its fiscal 2026 revenue guidance and reported decelerating sales and contracting net income.
● Class Period & Defendants: The class period runs from August 8, 2024, through May 13, 2026, inclusive. The named defendants are Doximity, Inc., Jeffrey Tangney (co-founder and Chief Executive Officer), Anna Bryson (Chief Financial Officer from May 11, 2021 to April 13, 2026), Nate Gross (co-founder and Chief Strategy Officer from 2010 until June 13, 2025), and Perry Gold (Vice President of Investor Relations & Revenue Operations).
● Lead Plaintiff Deadline: November 16, 2026. Investors who wish to seek appointment as lead plaintiff must apply by the deadline.
|
Doximity Class Action Summary |
|
|
Company |
Doximity, Inc. (NYSE: DOCS) |
|
Lead Plaintiff Deadline |
November 16, 2026 |
|
Class Period |
August 8, 2024 – May 13, 2026 |
|
Stock Drop |
November 6, 2025 – DOCS fell $8.29 (13%); February 5, 2026 – DOCS fell $5.59 (17%); May 13, 2026 disclosure – DOCS fell $5.38 (23%), closing at $18.01 on May 14 |
A securities class action has been filed against Doximity, Inc. (NYSE: DOCS). The named plaintiff is the Michigan Laborers' Pension Fund. The case covers investors who bought Doximity common stock between August 8, 2024, and May 13, 2026.
The complaint alleges that Doximity made materially false and misleading statements about its business. It claims the company overstated how much its "Newsfeed" product drove revenue growth. The lawsuit also alleges Doximity was losing market share to rivals and used banner ads and email newsletters even as it publicly denied doing so.
The complaint says the truth came out through three disclosures. The stock fell 13% in November 2025, 17% in February 2026, and 23% in May 2026. The lawsuit alleges investors suffered significant losses as a result.
Doximity, Inc. is a digital platform for U.S. medical professionals that combines health care news, workflow products, and clinician networking, and is frequently referred to as the "LinkedIn for doctors." The company generates nearly all of its revenue through its Marketing Solutions segment, which sells digital advertising subscriptions to customers such as pharmaceutical companies and hospitals, with most ads placed on its social-media-style "Newsfeed." Doximity is headquartered in San Francisco, California, and its shares trade on the NYSE under the ticker symbol "DOCS."
August 8, 2024 – May 13, 2026
Investors who purchased or otherwise acquired Doximity, Inc. (DOCS) common stock during the Class Period and suffered financial losses may be eligible to seek recovery under the federal securities laws.
The complaint alleges that throughout the Class Period, Doximity marketed itself as a "deep engagement" advertising platform, distinguishing itself from competitors that rely on "light engagement" methods such as passive banner ads and email blasts. Doximity described a "deep engagement" as a "click" by a user to reach full-length content, which it framed as evidence of genuine intent to view an advertisement. The company repeatedly told investors that its Newsfeed was its "biggest revenue driver" and its "most used and most monetized product."
According to the complaint, defendants, and Chief Executive Officer Jeffrey Tangney in particular, made a series of statements on earnings calls and in SEC filings touting record engagement on the Newsfeed. The lawsuit points to statements that the Newsfeed was "reach[ing] new highs," that the company had "an all-time record of quarterly active prescribers and double-digit growth in the number of articles read or tapped," and that Doximity was "gaining share . . . against our competition." On a May 15, 2025 call, when asked about engagement through an e-newsletter product, Tangney allegedly replied strongly that "we don't have an e-newsletter product."
The complaint alleges these statements were materially false and misleading. In truth, according to the filing, Doximity overstated the impact its Newsfeed had on revenue growth and was losing market share to competitors with more favorable pricing and engagement models. The lawsuit further alleges that, contrary to its public representations, Doximity relied heavily on both banner ads and email newsletters as advertising methods.
The complaint alleges that defendants knew or recklessly disregarded that these representations were false. It states that Tangney and then-Chief Financial Officer Anna Bryson had unfettered access to the company's internal data, including an internal dashboard, and that Tangney expressly denied the existence of an e-newsletter product when questioned by analysts. These facts, the complaint alleges, collectively give rise to a strong inference of scienter.
The complaint alleges the truth began to emerge on November 6, 2025, when Doximity expressed caution regarding the outlook for advertising spending and implied a slowdown in sales growth for the second half of its 2026 fiscal year. Following that disclosure, the price of Doximity common stock declined by $8.29 per share, or 13%. On the same day, the complaint notes, Tangney continued to attribute the company's performance to record Newsfeed engagement.
The lawsuit alleges the picture worsened when Doximity lowered its fiscal 2026 revenue guidance on February 5, 2026, and announced that sales growth had decelerated while net income had contracted. Analysts reacted by questioning the company's assurances, with one Evercore analyst noting that older companies like Doximity "are losing share while programmatic, social, and other new formats are gaining share." The stock declined by $5.59 per share, or 17%, after these disclosures.
Then, on May 13, 2026, the complaint alleges Doximity announced it had missed its already-reduced revenue guidance and projected a significantly slower pace of growth for its 2027 fiscal year. Several analysts downgraded the stock, with one describing the news as "a tough pill to swallow" as shares fell to "an all-time low," others placing the stock "in the penalty box," and RBC Capital Markets noting that stalled net revenue retention suggested an "increasingly competitive market." The stock declined an additional $5.38 per share, or 23%.
According to the complaint, the price of Doximity common stock fell across three separate disclosures. On November 6, 2025, the stock declined $8.29 per share, or 13%, after the company signaled caution about advertising spending and a second-half slowdown. On February 5, 2026, the stock declined $5.59 per share, or 17%, after Doximity lowered its fiscal 2026 revenue guidance and reported decelerating sales and contracting net income.
The steepest drop came on May 13, 2026, when the company missed its already-reduced guidance and projected significantly slower growth for fiscal 2027. Doximity common stock declined $5.38 per share, or 23%, from a closing price of $23.39 on May 13, 2026, to a closing price of $18.01 on May 14, 2026. The complaint alleges these declines caused significant losses for investors who purchased Doximity common stock during the Class Period.
● Lead Plaintiff Deadline: November 16, 2026
● After the lead plaintiff deadline, the Court will consider any lead plaintiff motions.
● Defendants may file a motion to dismiss.
● If the case proceeds, the Court may later consider class certification.
Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. Prior results do not guarantee similar outcomes.
The complaint alleges that Doximity, Inc. (NYSE: DOCS) made materially false and misleading statements about its advertising business between August 8, 2024, and May 13, 2026. According to the complaint, Doximity overstated the impact its "Newsfeed" product had on revenue growth and was losing market share to competitors with more favorable pricing and engagement models. The lawsuit also alleges that, despite publicly denying it used banner ads or email newsletters, Doximity relied heavily on both of those advertising methods. Investors who purchased or otherwise acquired Doximity common stock during the Class Period and suffered financial losses may be eligible to seek recovery under the federal securities laws.
The complaint names Doximity, Inc. and four individual defendants. They are Jeffrey Tangney, the company's co-founder and Chief Executive Officer; Anna Bryson, who served as Chief Financial Officer from May 11, 2021 to April 13, 2026; Nate Gross, co-founder and Chief Strategy Officer from 2010 until June 13, 2025; and Perry Gold, Vice President of Investor Relations & Revenue Operations. According to the complaint, the individual defendants had the power and authority to control the contents of Doximity's public statements and SEC filings during the class period.
The class period runs from August 8, 2024, through May 13, 2026, inclusive. The complaint alleges that during this time, defendants made materially false and misleading statements about Doximity's Newsfeed engagement, its competitive position, and its use of banner ads and email newsletters. Investors who purchased or otherwise acquired Doximity common stock during this period and suffered financial losses may be eligible to seek recovery under the federal securities laws. The class period begins with the company's August 8, 2024 first quarter fiscal 2025 results and ends with its May 13, 2026 disclosure.
According to the complaint, Doximity common stock declined across three disclosures. On November 6, 2025, the stock fell $8.29 per share, or 13%, after the company signaled caution on ad spending. On February 5, 2026, it fell $5.59 per share, or 17%, after Doximity lowered its fiscal 2026 revenue guidance. Following the May 13 disclosure, Doximity common stock fell $5.38 per share, or 23%, from $23.39 on May 13 to $18.01 on May 14, after the company missed its reduced guidance and projected slower growth for fiscal 2027.
The complaint alleges Doximity concealed that it was overstating how much its Newsfeed product drove revenue growth. It further alleges the company was losing market share to competitors offering more favorable pricing and engagement models. According to the complaint, Doximity also relied heavily on banner ads and email newsletters, even though it publicly assured investors it did not "bombard physicians with ads" and that it did not have an e-newsletter product. The lawsuit claims these omissions kept the stock price artificially inflated until the truth emerged.
The named plaintiff is the Michigan Laborers' Pension Fund, a pension fund established to provide medical, pension, annuity, and other benefits for eligible members and their dependents. According to the complaint, the plaintiff purchased Doximity common stock at artificially inflated prices during the class period and suffered damages as a result of the alleged violations of the federal securities laws. The lawsuit was filed in the United States District Court for the Northern District of California under case number 3:26-cv-10529.
The lead plaintiff deadline is November 16, 2026.
The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. Count I alleges that all defendants made materially false and misleading statements and omissions that artificially inflated the price of Doximity common stock. Count II alleges that the individual defendants acted as controlling persons of Doximity and are therefore liable under Section 20(a). According to the complaint, defendants knew or recklessly disregarded that their statements were false and misleading.
The complaint alleges Doximity (NYSE: DOCS) overstated how much its Newsfeed product drove revenue and hid that it was losing market share and using banner ads and email newsletters it publicly denied using.
The class period runs from August 8, 2024, through May 13, 2026, inclusive. Investors who purchased or otherwise acquired Doximity common stock during this period and suffered financial losses may be eligible to seek recovery under the federal securities laws.
Following the May 13, 2026 disclosure, Doximity stock fell 23%, closing at $18.01 on May 14 after a $5.38 per-share decline.
The named plaintiff is the Michigan Laborers' Pension Fund, which the complaint alleges purchased Doximity common stock at artificially inflated prices and suffered damages.
The lead plaintiff deadline is November 16, 2026.
Deadline
Nov 16, 2026